# Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

> **NCT01664923** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 396 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Enzalutamide
- **DRUG:** Bicalutamide

## Key facts

- **NCT ID:** NCT01664923
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08
- **Primary completion:** 2015-02
- **Final completion:** 2018-01
- **Target enrollment:** 396 (ACTUAL)
- **Last updated:** 2019-01-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01664923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01664923, "Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01664923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*